Literature DB >> 23287624

Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.

Bob Löwenberg1.   

Abstract

High-dose cytarabine applied during remission induction or as consolidation after attainment of a complete remission has become an established element in the treatment of adults with acute myeloid leukemia. Recent evidence has challenged the need for these exceptionally high-dose levels of cytarabine. In this review, we present a reappraisal of the usefulness of high-dose cytarabine for acute myeloid leukemia treatment.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23287624     DOI： 10.1182/blood-2012-07-444851

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  46 in total

Review 1.  Cytotoxic therapy in acute myeloid leukemia: not quite dead yet.

Authors:  Laura C Michaelis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Progress in acute myeloid leukemia.

Authors:  Tapan M Kadia; Farhad Ravandi; Susan O'Brien; Jorge Cortes; Hagop M Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-09-19

Review 3.  Frontline treatment of acute myeloid leukemia in adults.

Authors:  Gevorg Tamamyan; Tapan Kadia; Farhad Ravandi; Gautam Borthakur; Jorge Cortes; Elias Jabbour; Naval Daver; Maro Ohanian; Hagop Kantarjian; Marina Konopleva
Journal:  Crit Rev Oncol Hematol       Date:  2016-12-11       Impact factor: 6.312

Review 4.  Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Authors:  Maximilian Stahl; Benjamin Y Lu; Tae Kon Kim; Amer M Zeidan
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

Review 5.  Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?

Authors:  Benjamin A Derman; Richard A Larson
Journal:  Best Pract Res Clin Haematol       Date:  2019-10-18       Impact factor: 3.020

Review 6.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

7.  c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis.

Authors:  Arash Nanbakhsh; Cécile Pochon; Aude Mallavialle; Sophie Amsellem; Jean Henri Bourhis; Salem Chouaib
Journal:  Blood       Date:  2014-03-27       Impact factor: 22.113

Review 8.  Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.

Authors:  Jennifer Davila; Emily Slotkin; Thomas Renaud
Journal:  Paediatr Drugs       Date:  2014-04       Impact factor: 3.022

9.  Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.

Authors:  Ji-Hao Zhou; Hai-Qing Lin; Qi Shen; Li-Na Hu; Guo-Qiang Li; Xiong-Fei Sun; Xin-You Zhang
Journal:  Curr Med Sci       Date:  2018-03-15

10.  Comparative study of autophagy inhibition by 3MA and CQ on Cytarabine‑induced death of leukaemia cells.

Authors:  Caroline Palmeira dos Santos; Gustavo J S Pereira; Christiano M V Barbosa; Aron Jurkiewicz; Soraya S Smaili; Claudia Bincoletto
Journal:  J Cancer Res Clin Oncol       Date:  2014-06       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.